Why Most Medical Research Is Funded by the Industry It Studies
June 7, 2026 · Frisian News
Pharmaceutical companies fund roughly 60 percent of clinical trials in the United States, creating a fundamental conflict of interest. Trials funded by drug makers are three to five times more likely to reach conclusions favoring the sponsor's product than independent research.
Pharmaceutical companies fund the majority of clinical trials in the United States. This creates an obvious problem: the industry pays for most of the research that claims to prove its own products work. Independent research exists, but it is rarer and less visible than industry-sponsored studies that find favorable results.
The numbers are stark. Trials funded by drug makers are significantly more likely to reach conclusions favoring the sponsor's product than trials funded by government or nonprofits. The bias is not always dishonest, it is structural. Researchers know which company signed the check.
The problem goes beyond individual studies. Pharmaceutical companies choose which drugs to study, not governments or independent researchers. Expensive patented medicines get hundreds of trials. Cheap generic drugs that work but generate no profit get almost none. Cancer patients may have a dozen treatment options studied in detail, while rare disease sufferers have almost nothing.
Medical journals and universities claim to police this conflict. They publish conflict-of-interest statements and editorial guidelines. Then they publish the same industry-funded research anyway, because it attracts subscribers and advertising revenue. The institutions that are supposed to be gatekeepers profit from the gate they claim to guard.
Doctors prescribe based on what the research says. Patients trust their doctors. Neither group asks who wrote the check. Until that question becomes routine, pharmaceutical companies will own the evidence base that justifies their products.
Published June 7, 2026 · Frisian News